首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2017年 7期肝癌的诊断和非手术治疗 => 专家论坛 =>肝炎病毒相关性肝细胞..
肝炎病毒相关性肝细胞癌的抗病毒治疗现状与挑战
Antiviral therapy for hepatitis virus-related hepatocellular carcinoma: current status and challenges
文章发布日期:2017年06月07日  来源:  作者:董菁,江家骥  点击次数:1959次  下载次数:441次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:全球肝细胞癌(HCC)发生率在上升,东亚和我国部分地区呈下降趋势,但在我国仍属于发病率和病死率靠前的疾病。研究提示抗病毒治疗如能长期将HBV复制抑制至极低水平或使HCV感染者获得持续性病毒学应答,则可以降低病毒相关性HCC的发生率。新证据提示PEG-IFNα较核苷类药物和(或)核苷酸类药物具有更好的二级预防作用;IFN类在病毒相关性HCC的三级预防中扮演重要作用。回顾了近两年病毒相关性HCC的流行病学研究和抗病毒治疗在二级/三级预防中的作用,指出充分有效抗病毒治疗是防止HCC发生、复发的基础。
【Abstract】:The incidence rate of hepatocellular carcinoma (HCC) is increasing around the world and tends to decrease in East Asia and several regions in China; however, China still has higher incidence rate and mortality rate of HCC than most countries. Studies have shown that long-term antiviral therapy can inhibit HBV replication to a very low level or help patients with HCV infection achieve sustained virologic response, which can further reduce the incidence rate of virus-related HCC. New evidence suggests that compared with nucleos(t)ide analogues, PEG-IFNα has a better effect of secondary prevention. Studies also indicate that interferons play an important role in tertiary prevention of virus-related HCC. This article reviews the epidemiological studies on virus-related HCC in recent years and the role of antiviral therapy in second and tertiary prevention and points out that adequate and effective antiviral therapy is the basis for preventing the development and recurrence of HCC.
【关键字】:癌, 肝细胞; 肝炎病毒; 抗病毒药; 治疗
【Key words】:carcinoma, hepatocellular; hepatitis viruses; antiviral agents;therapy
【引证本文】:董菁, 江家骥. 肝炎病毒相关性肝细胞癌的抗病毒治疗现状与挑战[J]. 临床肝胆病杂志, 2017, 33(7): 1270-1273.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号